Late Toxicity of Radiotherapy and Chemotherapy in Hodgkin Lymphoma

News
Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This interview examines treatment-related cardiotoxicity and the risk of second malignancy in patients with Hodgkin lymphoma.

Treatment-related cardiotoxicity and the risk of second malignancy in survivors of Hodgkin lymphoma who received radiation therapy or chemotherapy is an important consideration given the high cure rate for this disease.

In this interview, Flora van Leeuwen, PhD, of the Netherlands Cancer Institute, discusses strategies to reduce the risk of these late toxicities and highlights some of the key points from an education session she presented at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Content
Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

Roman Fabbricatore
February 4th 2025
Article

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

CD19-directed CAR T therapy for T-cell/histiocyte-rich large B-cell lymphoma

CD19-directed CAR T therapy for T-cell/histiocyte-rich large B-cell lymphoma

American Society for Transplantation and Cellular Therapy
January 28th 2025
Article

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Ariana Pelosci
January 24th 2025
Article

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.

FDA Puts Clinical Hold on Tabelecleucel in EBV+ PTLD, ATA3219 in Lymphoma

Russ Conroy
January 23rd 2025
Article

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.